{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.9","upperLimit":"12.3","value":"8.8"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.6","upperLimit":"17.1","value":"13.0"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"12.0","value":"8.5"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"331"}],"units":"Participants"}],"description":"Patients counted in this variable were a subset of those in Point 1 above, where both the numerator and denominator were only counting patients with negative conventional imaging (according to investigator assessment) for M1 disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"all patients who received rhPSMA-7.3 (18F) injection followed by a PET scan. This population included M0 and M1 patients independent of performance of RP and PLND and was used for M1 related efficacy and Kappa statistics.","id":"OG000","title":"Extended Efficacy Population (EEP)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration","title":"Percentage of Patients With Negative Conventional Imaging for M1 Disease in Whom rhPSMA-7.3 (18F) PET Detected at Least One Verified M1 Metastasis, as Determined by Central BIE (Objective 2)","type":"SECONDARY","unitOfMeasure":"percentage"}